Neuropatía

Las drogas contra la disfunción eréctil y la NOIANA

Revisión de evidencias recientes sobre inhibidores FDE5 y el riesgo de neuropatía óptica isquémica anterior no arterítica (NOIANA)

Autor/a: Dres. Helen V. Danesh-Meyer, Leonard A. Levin

Fuente: Br J Ophthalmol 2007;91:1551–1555

Indice
1. Bibliografía
2. Desarrollo

1 Fink HA, MacDonald R, Rutks IR, et al. Sildenafil for male erectile dysfunction. Arch Intern Med 2002;162:1349–60.
2 Konstantinos H, Dimitrios H. Phosphodiesterase type 5 inhibitors: the day after.  Eur Urol 2007;51:75–89.
3 Health Canada. Association of the erectile dysfunction medications Cialis
(tadalafil), Levitra (vardenafil hydrochloride) and Viagra (sildenafil citrate) with
visual problems (Dear Health Care Professional letter). Ottawa: Health Canada, 2006 June 19. Available: www.hc-sc.gc.ca/dhp-mps/medeff/ advisories-avis/prof/2006/cialis_levitra_viagra_hpc-cps_e.html (accessed 2006 Jul 21).
4 Fraunfelder FW, Fraundfelder FT. Scientific challenges in postmarketing
surveillance of ocular adverse drug reactions. Am J Ophthalmol 2007; 143:145–9.
5 Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and
recommendations for its use. Am J Cardiol 1999;84:11–17N.
6 Strom BL. Sample size considerations for pharmacoepidemiology studies. In:Strom BL, eds. Pharmacoepidemiology, 4th edition.Chichester: John Wiley & Sons, 2005:29–36.